Using lower cost statins improves outcomes for normal cholesterol non-diabetic patients

References

• Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207.
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. J Am Med Assoc. 1998;279(20):1615–1622.
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomized controlled trial. Lancet. 2006;368(9542):1155–1163.
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol. 2014;63(25b):2889–2934.
   PubMed Web of Science ®Google Scholar
• Pencina MJ, Navar-Boggan AM, D’Agostino RB, et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med. 2014;370(15):1422–1431.
   Web of Science ®Google Scholar
• Pursnani A, Massaro JM, D’Agostino RB, et al. Guideline-based statin eligibility, coronary artery calcification, and cardiovascular events. Jama. 2015;314(2):134–141.
   PubMed Web of Science ®Google Scholar
• Slejko J, Page R, Sullivan P. Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER. Curr Med Res Opin. 2010;26(10):2485–2497.
   PubMed Web of Science ®Google Scholar
• Choudhry NK, Patrick AR, Glynn RJ, et al. The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels. J Am Coll Cardiol. 2011;57(7):784–791.
   PubMed Web of Science ®Google Scholar
• Pandya A, Sy S, Cho S, et al. Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease. Jama. 2015;314(2):142–150.
   PubMed Web of Science ®Google Scholar
• Ioannidis JPA. More than a billion people taking statins?: potential implications of the new cardiovascular guidelines. Jama. 2014;311(5):463–464.
   PubMed Web of Science ®Google Scholar
• Pencina MJ, Navar-Boggan AM, D’Agostino RB, et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med. 2014;370(15):1422–1431.
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ispor 2012 budget impact analysis good practice ii task force. Value In Health. 2014;17(1):5–14.
   PubMed Web of Science ®Google Scholar
• Garattini L. Van de Vooren K. Budget impact analysis in economic evaluation: a proposal for a clearer definition. Eur J Heal Econ. 2011;12(6):499–502.
   PubMed Web of Science ®Google Scholar
• Dunn AG, Braithwaite J, Gallego B, et al. Nation-scale adoption of new medicines by doctors: an application of the Bass diffusion model. BMC Health Serv Res. 2012;12(1):1–9.
   PubMed Web of Science ®Google Scholar
• Muller E, Yogev G. When does the majority become a majority? Empirical analysis of the time at which main market adopters purchase the bulk of our sales. Technol Forecast Soc Change. 2006;73(9):1107–1120.
   Web of Science ®Google Scholar
• Arbel R, Yogev G, Greenberg D. Diffusion of innovations in health care: does the dual market phenomenon exist? Value Heal. 2011;14(7):A338.
   Web of Science ®Google Scholar
• Bergheanu SC, Reijmers T, Zwinderman AH, et al. Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins. Curr Med Res Opin. 2008;24(9):2477–2487.
   PubMed Web of Science ®Google Scholar
• Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol. 2003;92(2):152–160.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Brandrup-Wognsen G, Palmer M, et al. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from voyager). Am J Cardiol. 2010;105(1):69–76.
   PubMed Web of Science ®Google Scholar
• Neumann A, Maura G, Weill A, et al. Comparative effectiveness of rosuvastatin versus simvastatin in primary prevention among new users: a cohort study in the French national health insurance database. Pharmacoepidemiol Drug Saf. 2014;23(3):240–250.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Rahme E, Pilote L. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J. 2006;151(2):273–281.
   PubMed Web of Science ®Google Scholar
• Ridker PM, MacFadyen JG, Fonseca FAH, et al. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention. Circ Cardiovasc Qual Outcomes. 2009;2(6):616–623.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011;378(9798):1231–1243.
   PubMed Web of Science ®Google Scholar
• Nelson AL, Cohen JT, Greenberg D, et al. Much cheaper, almost as good: decrementally cost-effective medical innovation. Ann Intern Med. 2009;151(9):662–667.
   PubMed Web of Science ®Google Scholar